GENETIC TECHNOLOGIES ADR REP 3 (GENE)

  • GENE-Infos

    Da geht was:


    ASX ANNOUNCEMENT


    8 August 2018


    ___________________________________________________________________________________


    Genetic Technologies Secures A$20 Million


    Equity Placement Facility


    Melbourne, Australia, 8 August 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a A$20 million Equity Placement Facility (the “Facility”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment management firm, to strengthen the Company’s funding position.


    Under the Facility, Kentgrove Capital may provide the Company with up to A$20 million of equity capital in a series of individual placements of up to $1 million (or a higher amount by mutual agreement) over the next 20 months. Proceeds from the Facility will be used for general working capital purposes and to fund the Company’s activities as it seeks to:


     commercialise existing R&D capabilities, IP and introduce an enhanced BREVAGenplus breast cancer risk assessment test and a colon cancer risk assessment test;


     progress development of a suite of genetic screening tests targeting both cancer and non-oncological diseases utilising the latest technology and platforms, and


     explore and capitalise on Blockchain opportunities in the medical and biotech industries.



    Drawdowns under the Facility occur based on terms set by the Company, including the timing, drawdown amount and minimum issue price.


    Commenting on the Facility, Genetic Technologies’ Chairman, Dr Paul Kasian said: “We are delighted to have signed the A$20 million Facility with Kentgrove Capital. Subject to the terms outlined below, the Facility will assist the Company with its ongoing funding requirements as it seeks to develop a range of risk prediction tests that are designed to assist in the early detection of cancer and help physicians improve patient outcomes. Blockchain technology presents a unique opportunity for the Company to further contribute to the advancement of cancer research.”


    Key terms of the Equity Placement Facility


    1. Facility amount of up to A$20,000,000.


    2. Maturity date 7 April 2020 (20 months from date of execution).


    3. Genetic Technologies may undertake multiple placements under the Facility, up to the maturity date.


    4. For each new placement, Genetic Technologies determines the time period of the placement, the maximum amount of the placement (up to A$1 million, or an amount equal to the total


    number of collateral shares (defined below) on issue multiplied by the minimum issue price, or a higher amount by mutual agreement) and the minimum issue price.


    5. For each new placement, shares are issued at a 4.5% discount to a volume weighted average price (VWAP) of the shares traded by Kentgrove Capital over the period of the placement, but cannot be less than the minimum issue price determined by Genetic Technologies.


    6. The issuance of shares under the Facility is required to be in compliance with ASX Listing Rule 7.1. Initial drawdowns under the Facility may be made within the Company’s current placement capacity. Shareholder approval in relation to the balance of the Facility may be sought at a General Meeting as required.


    7. The provision of funding by Kentgrove Capital under the Facility is subject to a number of conditions, including that the market price be no lower than the minimum issue price set by Genetic Technologies, and other conditions customarily included in facilities of this nature.


    8. An upfront establishment fee satisfied by the issue to Kentgrove Capital of 8,833,100 shares and 12,500,000 3-year options with an exercise price per option of $0.0153.


    9. 100,000,000 collateral shares will be issued to Kentgrove Capital on execution as security for the Facility. Upon termination or expiration of the Facility, any outstanding collateral shares will be, at the Company’s election, sold by Kentgrove Capital and the proceeds returned to the Company (less a discount of 4.5%) or bought back by the Company for a nominal figure.


    10. Either the Company or Kentgrove Capital may terminate the Facility, by giving 14 days' notice, other than during the first 90 days of the Facility during which it may only be terminated with cause, in accordance with the termination provisions as defined within the Facility.


    11. Kentgrove Capital has given an undertaking to the Company that it will not, during the 3 months following the execution of the Facility, exercise the establishment options or dispose of the establishment fee shares.



    Further details regarding the Facility will be provided in the prospectus required to be lodged by the Company in conjunction with the Facility


    -----------------------------------------------------------------------------------------------------------------------


    FOR FURTHER INFORMATION PLEASE CONTACT


    Dr Paul Kasian Jason Wong (USA))


    Director & Interim CEO Blueprint Life Science Group


    Genetic Technologies Limited +1 (415) 375 3340, Ext. 4


    + 61 3 8412 7000 Genetic Technologies Limited Website: http://www.gtglabs.comEmail: info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040



    Weiter:


    ASX ANNOUNCEMENT


    8 August 2018


    Lodgement of Prospectus


    Melbourne, Australia, 8 August 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE,


    Company”, “GTG”) is pleased to advise that it has lodged the attached Prospectus with ASIC.


    The Company recently announced that it has entered into a $20million equity placement facility with


    Kentgrove Capital Pty Ltd ACN 150 638 627 (Kentgrove) to strengthen the Company’s funding position.


    Following the execution of the Kentgrove facility and under the Prospectus, the Company will offer and issue to Kentgrove:


     8,833,100 Shares in lieu of payment of the Establishment Fee (Establishment Shares);


     12,500,000 Options exercisable at $0.0153 each and expiring 3 years after issue


    (Establishment Options); and


     100,000,000 Shares as security for the Company's obligations under the Kentgrove Facility


    (Collateral Shares).


    Under the Prospectus, the Company will also have the ability to offer and issue up to 441,655,004


    Shares (Placement Shares) either to Kentgrove under the Kentgrove Facility, or to other investors as


    determined by the board, to raise up to $5,000,000.


    An Appendix 3B is also attached with respect to the offers being made under the Prospectus.



    FOR FURTHER INFORMATION PLEASE CONTACT


    Dr Paul Kasian


    Chairman and Interim CEO


    Genetic Technologies Limited


    + 61 3 8412 7000



    Weiter:


    ASX ANNOUNCEMENT


    7 August 2018


    Swisstec Update


    Melbourne, Australia, 7 August 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, provides the following updates to recent announcements with regards to collaborations with Swisstec Health Analytics Ltd. (“Swisstec”).


    1. Progress on Swisstec Heads of Agreement


    The Sunset period to finalise a Proposed Joint Venture (refer 19 June 2018 announcement) to establish a new company to enable Swisstec and the Company to collaborate to develop a medical and health service platform using blockchain technology has expired. However, neither party has terminated the Heads of Agreement and the Heads of Agreement remains on foot unless it is subsequently terminated by either party on notice. The Company continues to progress discussions with Swisstec regarding the establishment of this new joint venture company and the parties are continuing to work together to identify potential collaborative opportunities.


    2. Arrangements with Swisstec regarding Asian distribution


    The Company wishes to clarify that the agreement recently entered with Swisstec (refer 30 July 2018 announcement) sets out the principal commercial terms on which the Company intends to appoint Swisstec as a non-exclusive distributor for hospitals in Asia, and imposes binding obligations on the parties to negotiate in good faith in order to enter a formal distribution agreement. It is expected that formalisation and entry of a distribution agreement will occur once Swisstec has presented the Company with formal proposals for specific hospitals in the Asian region. Further updates will be provided in this regard as required.



    FOR FURTHER INFORMATION PLEASE CONTACT


    Dr Paul Kasian Jason Wong (USA)


    Chairman and Interim CEO Blueprint Life Science Group


    Genetic Technologies Limited +1 (415) 375 3340, Ext. 4


    + 61 3 8412 7000

    Emil

  • GENE-News


    Gute News heute:


    ASX ANNOUNCEMENT


    17 September 2018


    GTG Invited to Establish a Market Presence in Hainan, China


    Melbourne, Australia, 17 September 2018: Hainan Resort Software Community(“HRSC”) has on behalf of Hainan Ecological Smart City Group (“HESCG”) formally extended an invitation to Genetic Technologies Limited (“GTG”) to establish its planned market entry into China via the Hainan Free Trade Zone initiative. As previously reported to the market on 21 August 2018, participants in the Hainan Medical Pilot Zone gain access to the Chinese healthcare market with an estimated value in excess of US$800B. Companies approved to operate in China as part of the Hainan Free Trade Zone Initiative can take advantage of significant tax benefits, subsidies and investment.


    HRSC will also support GTG’s market entry through the provision of services including;


     Chinese company registration,


     Free office space in the zone,


     Marketing assistance – providing a link with government sectors, hospitals and enterprise,


     Assist in process to obtain CFDA approval for GTG’s risk assessment tests; this will dramatically fastrack the process,


     Obtain test samples to undertake new product development for the Chinese ethnic population.



    The formal invitation follows on from a recent visit to Hainan by GTG’s CEO, Dr Paul Kasian and representatives from Beijing Zishan Health Consultancy Limited (“Zishan”), with whom GTG has signed a Heads of Agreement (as announced to the market on 14 August 2018).


    Dr Paul Kasian, Genetic Technologies’ Chairman commented: “The invitation is a significant first step to advance the adoption of genetic risk assessment tests in the region. We are grateful for the support we have received from HRSC and its commitment to continue to work with GTG to enable a successful outcome in China.”


    FOR FURTHER INFORMATION PLEASE CONTACT


    Dr Paul Kasian Jason Wong (USA)


    Chairman and Interim CEO Blueprint Life Science Group


    Genetic Technologies Limited +1 (415) 375 3340, Ext. 4


    + 61 3 8412 7000

  • Kursrutsch

    Hier ist man diese Woche auch mega steil abgestürzt. Was da wohl los war. Ich sehe keine News. Hat man einfach abgeräumt?

    Emil

  • Results und verlorene Beiträge

    Betr. verlorene Beiträge- Danke für die Info. Von dir Lorenz kann man im alten Forum noch einen Beitrag sehen hier vom 5. Jan. 2018. Da scheint schon einiges zu fehlen (?!).

    Emil

  • Info

    Die Info wollte ich noch weitergeben, ist aktuell von dieser Woche, am Donnerstag rausgekommen:


    http://www.globenewswire.com/n…shed-in-Hainan-China.htmlll, gestern rau


    April 11, 2019 09:15 ET | Source: Genetic Technologies Ltd


    Highlights

    • Genetic Technologies establishes Asian operations in China.
    • The move into Asia includes the formation of Genetic Technologies HK Limited and Hainan Aocheng Genetic Technologies Co. Ltd. in Hong Kong and Hainan, China respectively.
    • Genetic Technologies to gain access to the Chinese health market (1).

    MELBOURNE, Australia, April 11, 2019 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ: GENE) (“Company”), a provider of world-leading genetic risk assessment test products, is pleased to announce that it has now established its Asian operations within the Hainan Resort Software Community (“HRSC”) Free Trade Zone.


    Participants in the Hainan Medical Pilot Zone gain access to the Chinese healthcare market (1). As a part of the HRSC, Genetic Technologies will receive assistance in obtaining China FDA approval for the Company’s new and growing portfolio of genetic risk assessment tests, dramatically fast-tracking the ‘pathway to sales’ process. In addition, as a part of the HRSC, the Company can take advantage of significant tax benefits, subsidies, and facilitated investment.


    HRSC market entry support includes:

    • Marketing assistance – providing a link with government sectors, hospitals and other Chinese based health enterprises
    • Obtaining test samples to undertake new product development specifically for the Chinese ethnic population
    • Chinese corporate registry support
    • Office space in the Free Trade Zone precinct and complimentary accommodation for GTG staff
    • Provision of a Dedicated HRSC Business Development Director (Mr York Yin)

    “The Hainan Provincial Government has established a world-class technology zone in Hainan, and we are delighted that Genetic Technologies has joined the medical pilot precinct,” Mr Yin said.


    HRSC is owned by China Electronics Corporate (CEC), a State-Owned Enterprise of the China Central Government. The companies approved to operate in China as part of the Hainan Free Trade Zone Initiative can take advantage of significant tax benefits, subsidies, and facilitated investment.


    Dr Paul Kasian, Genetic Technologies’ Chairman and CEO, said, “The establishment of operations in Hainan China is a significant step to advance the adoption of genetic risk assessment tests in China and in due course other parts of Asia. We are grateful for the support we have received from HRSC to date and acknowledge their commitment to continue to work with GTG to provide a meaningful contribution to the Healthy China 2030 Policy.”


    The establishment of operations follows on from the formal invitation to Genetic Technologies from the Hainan Provincial Government (as announced to the market on 14 August 2018). This announcement referred to the Company forming a joint venture with Zishan for its China initiative; however, the joint venture approach will not be progressing at this time. Instead, Genetic Technologies, through its 100% owned subsidiary HAGT, will work to introduce its world-class genetic risk assessment tests to the Chinese market.


    Dr Kasian said, “This is likely to include partnering with Chinese health and medical distribution companies and CFDA accredited genetic testing laboratory operations. The HRSC team will help us find appropriate collaboration partners in mainland China. We hope that Genetic Technologies’ growing suite of world-leading genetic risk assessment test products will become central to China’s future preventative medicine activities.”


    (1) The Chinese Healthcare market has an estimated value in excess of US$925 billion – Statista Statistics Portal 2017


    FOR FURTHER INFORMATION PLEASE CONTACT


    Dr Paul Kasian
    Chairman and Interim CEO
    Genetic Technologies
    +61 3 8412 7000

    Mr Paul Viney
    COO, CFO and Company Secretary
    Genetic Technologies
    + 61 438 072 616

    Investor Relations and Media - Australia
    Karinza Phoenix
    StocksDigital
    +61 428 981 074
    karinza@stocksdigital.com

    Investor Relations and Media – USA
    Mr Dave Gentry
    RedChip
    Office: 1.800.RED.CHIP (733-2447)
    Cell: 407.491.4498
    Dave@RedChip.com

    About Genetic Technologies Limited


    Genetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.


    Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com


    Safe Harbor Statement


    Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

  • GENE-Info/ Berich Ende Juni 2019


    https://www.gtglabs.com/investor-centre


    Melbourne, Australia, 31 July 2019:


    Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a diversified molecular diagnostics company is pleased to provide its Quarterly Activities Report for the period ending 30 June 2019, together with the attached Appendix 4C.


    Highlights

    • • Intense focus on learnings and process improvement following the successful completion of the enhanced breast cancer and colorectal cancer polygenic genetic tests. GTG is determined to be the leading producer of polygenic tests targeted at the world’s most prolific diseases and in so doing, make a significant difference to the health outcomes of millions of people world-wide.
    • • The Company’s pipeline of genetic tests under development will now move towards timely completion of the ground-breaking Type 2 Diabetes test and the Cardiovascular Test.
    • • Following the Memorandum of Understanding signed with TGen Arizona – work continues on specific cooperation Agreements.
    • • Work continues with the Hainan Provincial Government to establish laboratory operations, product approvals and product distribution agreements in Hainan and also mainland China.
    • • Engagement with world-renowned US based, Asian Medical device distribution chain expert – discussions continuing.
    • • Work undertaken to commence monetization of GTG’s world-leading genetic test IP portfolio.
    • • AEGIS (US) broker mandate in place for capital market support. AEGIS led the recently successful US 1.2 million capital raise in May 2019, adding 2 institutional investors to GTG’s share register.
    • • Kentgrove Capital facility (AU) remains in place.
    • • Outsourced cost-effective accounting operations established with CFO Solutions of Melbourne. This work has enabled contemporary streamlined accounting processes to be introduced without the need for capital expenditure. • Distribution Channels
    • • Reimbursement Strategy
    • • Further Research
    • • Potential for Establishment of New Laboratory Facility

    Memorandum of Understanding (MoU) signed between GTG and The Translational Genomics Research Institute (TGen) of Phoenix, Arizona USA – next steps


    GTG recently announced that it has established an MoU with TGen. TGen is an Arizona-based, non-profit biomedical research institute dedicated to conducting ground-breaking research with life-changing results. TGen works to unravel the genetic components of common and complex diseases, including cancer, neurological disorders, infectious disease, and rare childhood disorders. TGen is affiliated with City of Hope in Duarte, California, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases


    The collaboration will be wide in scope covering:


    Key features include that GTG and TGen will cooperate in the development of a commercialisation strategy and infrastructure development for a suite of polygenic risk tests to be made available in the US market and establish any required fund-raising mechanisms. Work is well progressed for a Clinical Validation Study to be undertaken with TGen’s extensive network of cancer centre clinicians. 2


    Quarterly Activities Report for the quarter ended 30 June 2019


    GTG’s Product Development Pipeline


    Breast cancer test – announcing GeneType for Breast Cancer


    Development of an enhanced version of the Company’s legacy BREVAGenplus test is now completed – known as GeneType for Breast Cancer. The Company has formally launched the test, which will broaden the applicability of the legacy product BREVAGenplus and enable its use by women with an extended family history of disease. By increasing the range of risk factors analysed, the test will provide clinically actionable insight for approximately 95% of women.


    Announcing a world-leading Colorectal cancer test – GeneType for Colorectal Cancer


    Our first-to-market genetic risk assessment test for colorectal cancer has been completed. This is the first of a suite of ground-breaking new products GTG will deliver in the next 12 months.


    Other genetic risk assessment tests under development

    • • Cardiovascular Disease – target launch late 2019
    • • Type 2 Diabetes – target launch late 2019
    • • Prostate Cancer - 2020
    • • Melanoma - 2020

    GTG continues to explore operational expansion in China at the Hainan Resort Software Community ("HRSC") Free Trade Zone (Hainan, China)


    The move into China included the formation of Genetic Technologies HK Limited and Hainan Aocheng Genetic Technologies Co. Ltd. in Hong Kong and Hainan, China respectively. Genetic Technologies aims to gain access to the US$800 billion+ Chinese health market.


    As a part of the HRSC, GTG is receiving assistance in obtaining China FDA approval for the Company’s new and growing portfolio of genetic risk assessment tests. We aim to fast-track the ‘pathway to sales’ process. In addition, as a part of the HRSC, the Company can take advantage of significant tax benefits, subsidies, and facilitated investment. HRSC market entry support includes:

    • • Marketing assistance – providing a link with government sectors, hospitals and other Chinese based health enterprises
    • • Obtaining test samples to undertake new product development specifically for the Chinese ethnic population
    • • Chinese corporate registry support
    • • Office space in the Free Trade Zone precinct and complimentary accommodation for GTG staff
    • • Provision of a Dedicated HRSC Business Development Director

    The Chinese market is now the second biggest single healthcare market outside the United States. Over 4 million new cases of cancer are diagnosed in China every year. Breast cancer is increasing at a rate of over 3.5% each year.


    GTG’s market entry into China aligns with the government’s Healthy China 2030 initiative that seeks to provide cost-effective healthcare to more than 1.5 billion people. Disease prevention is critical to cost control as treatments for early stage disease carry a lower cost and result in better health outcomes. 3


    Quarterly Activities Report for the quarter ended 30 June 2019


    GTG’s genetic tests can be used to predict an individual’s likelihood of developing disease. Screening and other healthcare resources can be targeted to those with an elevated risk. For example, screening every woman for breast cancer may be too costly, but it may be cost-effective to preferentially screen those with a mid-to-high risk score.


    Capital – a successful US capital raise


    On 23 May 2019, the Company announced it had placed 1,476,143 American Depository Shares (ADSs) of the Company at an issue price of USD$0.80 per ADS with foreign institutional and sophisticated investors introduced by the Company's broker in the United States, Aegis Capital Corp. Each ADS represents 150 fully paid ordinary shares in the Company. GTG is pleased that it has established a strong and ongoing relationship with AEGIS and also with its Investor Relations advisors in the US and Australia.


    Management Changes


    GTG recently advised the following changes to the Executive Management Team.


    Chief Executive Officer


    The Company continues its recruitment process for a Chief Executive Officer. The Acting Chief Executive Officer, Dr Paul Kasian continues in that role until further notice.


    Chief Financial Officer / Chief Operating Officer / Company Secretary


    The Company announced that Mr Paul Viney has ceased to be CFO/COO and Company Secretary effective 15 July 2019. Mr Viney continues in a consulting capacity with the Company to ensure recent strategic momentum is maintained.


    Chief Financial Officer Appointment


    The Company announced that Mr Phillip Hains has been appointed CFO of GTG effective 15 July 2019. Mr Hains has an extensive background working in ASX and NASDAQ finance positions.


    New Company Secretary Appointment


    The Company announced that Mr Justyn Stedwell has been appointed Company Secretary effective 15 July 2019. Mr Stedwell is a professional Company Secretary consultant with over 12 years’ experience acting as a Company Secretary of ASX listed companies across a wide range of industries.


    Financial Snapshot


    Operational cash spend for the quarter continues to be well contained and declining – reflecting the Company’s strong cost focus and attention to delivering upon its research and development mandate. The Company’s cash receipts remained low as expected during this time of strategic transition, as investment in R&D, development of new product and distribution channels represent the major strategic and budgetary priorities for the Company. Shareholders can expect costs to remain contained during the remainder of 2019 and to see GTG focus strongly on product development and the establishment of distribution relationships in the US and Asia. 4


    Quarterly Activities Report for the quarter ended 30 June 2019


    Signed on behalf of Genetic Technologies Limited


    Date: 31 July 2019


    Dr Paul Kasian


    Chairman & Interim CEO



    Info:



    Melbourne, Australia, 30 July 2019: Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) today announced that it received a letter from The Nasdaq Stock Market informing the Company that it has failed to regain compliance with the $1.00 minimum bid price required for continued listing of its American Depositary Shares ("ADRs") on The Nasdaq Capital Market under Nasdaq Listing Rule 5450(a)(1), and as a result, the Company’s ADRs are subject to delisting.


    The Company intends to appeal the delisting determination to Nasdaq’s Hearings Panel, which will stay the delisting of the Company’s ADRs pending the hearing of the appeal and ultimate decision by the Hearings Panel. The Company intends to regain compliance with Nasdaq Listing Rule 5450(a)(1) while the appeal is pending by adjusting the ratio of its ADRs, each of which currently represents 150 of its ordinary shares.


    In addition to the Company’s noncompliance with Rule 5450(a)(1), and as previously reported, the Company received a letter from The Nasdaq Stock Market on April 29, 2019, advising the Company that it did not comply with Nasdaq Listing Rule 5550(b) because its stockholders' equity was less than US$2,500,000 as of December 31, 2018. In accordance with Nasdaq Listing Rules, the Company has submitted a plan to Nasdaq to regain compliance with the minimum stockholders’ equity rule by raising sufficient additional capital within 180 days of April 29, 2019. However, there can be no assurance the Company will be successful in that regard.


    Noncompliance with Nasdaq Listing Rules only applies to the Company's ADRs trading on the Nasdaq Capital Market, and not the Company's ordinary shares trading on the Australian Securities Exchange, the Company's home exchange.


    About Genetic Technologies Limited


    Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.


    Genetic Technologies is developing a pipeline of risk assessment products.


    For more information, please visit http://www.gtglabs.com

    Emil